Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22457542 | 1.00 | CASP3 (0.55) | CASP3KMT2ACTSLCTSBCTSS | |
| SCHEMBL24579472 | 0.91 | CASP3 (0.49) | CASP3KMT2ACTSLCTSBCTSS | |
| SCHEMBL29697620 | 0.91 | CASP3 (0.49) | CASP3KMT2ACTSLCTSBCTSS | |
| SCHEMBL24201042 | 0.90 | CASP3 (0.55) | CASP3KMT2ACTSLCTSBCTSS | |
| SCHEMBL29697791 | 0.89 | CASP3 (0.52) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29670259 | 0.88 | KMT2A (0.53) | CASP3KMT2ACTSLCTSBCTSS | |
| SCHEMBL5201071 | 0.86 | CASP3 (0.53) | CASP3KMT2ACTSLCTSBCTSS | |
| SCHEMBL29670125 | 0.86 | CASP3 (0.52) | CASP3KMT2ACTSLCTSBCTSS | |
| SCHEMBL24579473 | 0.85 | CASP3 (0.47) | CASP3KMT2ACTSLCTSBCTSS | |
| SCHEMBL29697699 | 0.85 | CASP3 (0.47) | CASP3KMT2ACTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NGLY1, NPPA, NPEPPS | CASP3 1076/4885KMT2A 3924/4885CTSL 36/4885 |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NGLY1, NPPA, NPEPPS | CASP3 1076/4885KMT2A 3924/4885CTSL 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.